BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/25/2025 12:09:46 PM | Browse: 26 | Download: 51
 |
Received |
|
2025-03-20 15:30 |
|
Peer-Review Started |
|
2025-03-31 00:08 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-09 12:50 |
|
Revised |
|
2025-04-27 03:03 |
|
Second Decision |
|
2025-07-01 02:47 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-07-02 02:14 |
|
Articles in Press |
|
2025-07-02 02:14 |
|
Publication Fee Transferred |
|
2025-04-28 07:29 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-07-13 08:59 |
|
Publish the Manuscript Online |
|
2025-07-25 12:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Molecular tumor boards in pancreatic cancer with liver metastasis: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan Yan, Zhi-Zhong Ren, Wen-Ya Wang, Jing Tang and Yue-Wei Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jing Tang, Associate Chief Pharmacist, Department of Clinical Pharmacy, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, No. 168 Litang Road, Changping District, Beijing, China, Beijing 102218, China. tj_0208@163.com |
| Key Words |
Pancreatic adenocarcinoma; BRCA2 mutation; Homologous recombination deficiency; Hepatic arterial infusion chemotherapy; Molecular tumor boards; Case report |
| Core Tip |
We report the case of a 45-year-old male with pancreatic head adenocarcinoma and liver metastases who underwent treatment with gemcitabine, albumin-bound paclitaxel, nimotuzumab, and proton radiotherapy. The tumor subsequently progressed, and the patient visited our molecular tumor boards (MTB) clinic. Repeat genetic testing revealed homologous recombination deficiency positivity (score 58) and a pathogenic BRCA2 mutation (p.T3033fs), prompting a shift to olaparib combined with immunotherapy (tislelizumab and atezolizumab) and hepatic arterial infusion chemotherapy (5-fluorouracil + leucovorin + oxaliplatin). This approach stabilized the disease and reduced liver metastases. MTB was crucial in interpreting genetic profiles and guiding personalized treatment, demonstrating the potential of MTB-driven strategies for treating advanced pancreatic cancer with liver metastases. |
| Publish Date |
2025-07-25 12:09 |
| Citation |
<p>Yan Y, Ren ZZ, Wang WY, Tang J, Zhang YW. Molecular tumor boards in pancreatic cancer with liver metastasis: A case report. <i>World J Hepatol</i> 2025; 17(7): 106993</p> |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i7/106993.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i7.106993 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
